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Objectives: The relative efficacy and safety of endarterectomy and stenting in patients with carotid stenosis remain unclear.
In this review we synthesize the available evidence derived from randomized controlled trials (RCTs) that compared the
two procedures in terms of the risks of death, stroke (disabling and nondisabling), and nonfatal myocardial infarction.
Methods: We searched for RCTs in MEDLINE, EMBASE, Current Contents, and Cochrane CENTRAL; expert files, and
bibliographies of included articles. Two reviewers, working independently, determined trial eligibility and extracted
descriptive, methodologic, and outcome data from each eligible RCT. Random-effects meta-analysis was used to assess
relative and absolute risks and the I2 statistic was used to assess heterogeneity of treatment effect among trials.
Results: Ten RCTs with 3182 participants proved eligible. At 30 days and compared with endarterectomy, carotid
stenting was associated with a nonsignificant reduction in the risk of death (relative risk [RR], 0.61; 95% confidence
interval [CI], 0.27-1.37; I2  0%), a nonsignificant reduction in the risk of nonfatal myocardial infarction (RR, 0.43; 95%
CI 0.17-1.11; I2  0%), and a nonsignificant increase in the risk of any stroke (RR, 1.29; 95% CI, 0.73-2.26; I2  40%)
and major/disabling stroke (RR, 1.06; 95% CI, 0.32-3.52; I2  45%). If one considers the two procedures equivalent if
the absolute difference in events is <2%, these results provide moderate-quality evidence for equivalence with respect
to death (risk difference [RD] 0.40, 95% CI 1.02 to 0.40) and nonfatal myocardial infarction (RD, 0.70; 95%
CI 1.90 to 0.50), but because of much wider CI, only low-quality evidence of equivalence in stroke (RD, 1.00; 95%
CI, 1.00 to 3.10).
Conclusion: In RCTs, carotid stenting and carotid endarterectomy seem equivalent in terms of death and nonfatal
myocardial infarction. Although the impact on stroke remains unestablished, results are consistent with a clinically
important increase in stroke risk with stenting, an intervention that aims at reducing the risk of stroke. ( J Vasc Surg
2008;48:487-93.)Randomized controlled trials (RCTs) have shown ca-
rotid endarterectomy (CEA) to reduce the incidence of
stroke and death in symptomatic and asymptomatic pa-
tients.1,2 Carotid angioplasty and stenting (CAS) has
emerged in the last decade as a feasible and less invasive
alternative, particularly for patients with multiple comor-
bidities who may have a high perioperative risk. Although
observational studies of angioplasty, later enhanced
through the use of stents and cerebral protective devices,
suggested that this procedure was safe and effective,3,4
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doi:10.1016/j.jvs.2008.05.035RCTs that compared CAS with CEA yielded heteroge-
neous and imprecise results. A meta-analysis of the RCTs
published through 2003 showed that imprecision persisted
despite pooling the results of individual trials.5
Seeking to provide guidance on the use of these proce-
dures, the Society of Vascular Surgery formed a task force
to formulate evidence-based clinical practice guidelines. To
guide the formulation of these guidelines and realizing that
several large trials have reported their findings since the
aforementioned meta-analysis was published, the task force
commissioned us to conduct a systematic review and meta-
analysis of RCTs comparing CAS with CEA. The task force
intended to evaluate the safety and the efficacy of the two
procedures and identify certain populations that may derive
differential benefits from the procedures, particularly, sub-
groups defined by the presence of symptoms, age, and
perioperative risk.
METHODS
The report of this protocol-driven systematic review
adheres to the Quality of Reporting of Meta-analyses
(QUOROM) standards for reporting systematic reviews of
RCTs.6
Eligibility criteria. We included RCTs that compared
CEA and CAS (with and without the use of cerebral pro-
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comes of interest were death, stroke, andmyocardial infarc-
tion (MI) at 30 days and 1 year after the procedure. We
included RCTs regardless of their publication status, lan-
guage, size, or duration of patient follow-up.
Study identification. An expert reference librarian
(P. J. E.) designed and conducted the electronic search
strategy with input from study investigators with exper-
tise in conducting systematic reviews. To identify eligible
studies, we searched electronic databases (MEDLINE,
EMBASE, Current Contents, and Cochrane CENTRAL
through the Ovid interface) from 2003 through April
2007. A published rigorous systematic review provided
references before October 2003.5 We also sought refer-
ences from experts, bibliographies of included trials, and
the Institute for Scientific Information (ISI) Science Cita-
tion Index for publications that cited included RCTs (de-
tails available from the authors upon request).
Two reviewers, working independently, screened all
abstracts and titles and, upon retrieval of candidate studies,
the full text publications for eligibility. Inter-reviewer
agreement was adequate (  0.85), and disagreements
were resolved by consensus.
Data collection. Two reviewers, working indepen-
dently and using a standardized form, extracted data from
all eligible RCTs, including RCTs identified in the 2003
review, which included:
● descriptive data—study size, number of patients in
each arm, patients’ age, the usage of stents and cerebral
protection devices, the presence of symptoms, the
length of follow-up, and the degree of stenosis;
● methodologic data—elements of bias protection such
as allocation concealment, blinding, proportions of
patients lost to follow-up, funding, and whether stud-
ies were stopped prematurely before reaching their
sample size; and
● outcome data—death, major and disabling stroke, any
stroke, Q-wave and non-Q wave MI.
We attempted to contact authors of all included RCTs by
e-mail to obtain missing data.
Statistical analysis
Meta-analyses. We pooled relative risks (RR) from
each trial using the DerSimonian-Laird random-effects
model7 and estimated the 95% confidence intervals (CI) for
the outcomes of death, major and disabling stroke, any
stroke, and Q-wave and non-Q wave nonfatal MI. We used
the I2 statistic, which estimates the percentage of total
variation across studies that is due to heterogeneity rather
than chance,8 that is, the percentage of variability in treat-
ment effects across trials that is not due to chance or
random error, but rather due to real differences in study
patients, design or interventions. Statistical analysis was
conducted by using Comprehensive Meta-Analysis version
2 software (2005; Biostat Inc, Englewood, NJ).
A key assumption in the interpretation of composite
end points is that there is a common treatment effect on itscomponents.9We found several RCTs reporting composite
end points in which the effect of treatment on the compo-
nents violated the assumption of a uniform underlying
treatment effect (ie, the intervention caused more strokes
but less deaths). Thus, we abandoned pooling composite
outcomes and pooled only the three individual outcomes of
interest.
Subgroup and sensitivity analyses. A priori hypoth-
eses to explain potential heterogeneity in the direction and
magnitude of effect among RCTs included patient-level
characteristics such as the presence of symptoms, age, gen-
der, diabetes status, history of renal failure, a prior stroke,
plaque morphology, and the severity of stenosis. In addi-
tion, we planned subgroup analysis based on trial-level
characteristics such as the surgical volume of operators, the
use of cerebral protection devices, and whether RCTs were
stopped prematurely before reaching their planned sample
size, a practice that may lead to overestimation of treatment
benefits.10 We anticipated that several trials might have
sparse data (zero events in one or both study arms), which
leads to a risk of zero and makes calculating relative risks
(risk ratios) impossible.
A standard statistical procedure is to add a very small
constant to all four cells in a two  two table to facilitate
ratio calculation. To ascertain the robustness of our analy-
sis, we repeated analysis by using three other different
constants (ie, three different continuity correction meth-
ods) to determine whether the choice of method affects
results. The analysis reported in this article follows the
treatment arm method for continuity correction, and sen-
sitivity analyses tested three other alternative continuity
correction methods (constant correction factors of 0.5 or
0.01, and the reciprocal of opposite arm size).11 In addi-
tion, we planned to conduct sensitivity analysis to deter-
mine the extent to which the inclusion of zero total events
trials (trials with no events in either arm) affected pooled
estimates.12
Equivalence analyses. We estimated the pooled risk
difference (RD) and CIs for each of the outcomes by
conducting random-effects meta-analyses of RDs derived
from individual trials. RCTs have used thresholds of equiv-
alence or noninferiority for composite end points that
Fig 1. Study selection. RCT, Randomized controlled trial.included our outcomes of interest that were in the range of
was 
was 
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between 2% and 3% on either side of no difference (RD, 0),
creating a region of equivalence (eg, from 3% to 3%
RD) for each outcome. To claim equivalence, the entire
confidence interval around the RD for an outcome should
reside within the region of equivalence.
RESULTS
Study identification. Fig 1 depicts the yield of our
search and selection procedures: of 498 potentially eligible
references, 10 proved eligible.13-22 Table I summarizes
their characteristics. These RCTs enrolled 3182 partici-
pants (mean size, 318 patients) who were a mean age of 68
years. In the 10 selected trials, the angioplasty procedures
included stenting, and in all selected trials published since
2004, the angioplasty procedures included the use of cere-
bral protection devices. The follow-up period ranged from
1 to 45 months, with most studies reporting 30-day out-
comes. Only one trial exclusively recruited asymptomatic
patients.18 Patients in all trials were deemed candidates for
both procedures, but in one trial they were selected when
they were deemed to have high risk for CEA.15 Authors
from 6 of the 10 RCTs responded to our queries and
provided data on individual outcomes in studies that re-
ported composite outcomes and explained randomization,
allocation, and blinding procedures.13,14,17-19,21
We excluded two trials from the main analysis: the
Carotid and Vertebral Artery Transluminal Angioplasty
Study (CAVATAS),19 in which only 26% of patients re-
ceived stents; and Leicester,21 in which there was no pre-
procedural imaging of the origin of the major head and
neck vessels to exclude contraindications to CAS, use of
nondedicated wall stents, and lack of routine predilation
technique. We considered these two trials to be inconsis-
tent with the contemporary CAS technique; however, we
Table I. Characteristics of included randomized trials
Author ( year) Trial name
Patients,
No.
Use of
stents
(%)
Use of cer
protect
devices
Naylor (1998)21 Leicester 23 100 0
Alberts (2001)16 Wallstent 219 100 0
Brooks (2001)17 Kentucky 104 100 0
CAVATAS (2001)19 CAVATAS 504 26 0
Brooks (2004)18 Kentucky 85 100 0
Yadav (2004)15 SAPPHIRE 334 100 95.6
Mas (2006)13 EVA-3S 527 100 91.9
The Space Group
(2006)14 SPACE 1200 100 NR (mix
Ling (2006)20 TESCAS-C 166 100 100
Hoffman (2006)22 BACASS 20 100 NR
BACASS, Basel carotid artery stenting study; CAVATAS, Carotid and Ver
Angioplasty in Patients With Symptomatic Severe Carotid Stenosis; NR, no
High Risk for Endarterectomy; SPACE, Stent-Protected Percutaneous A
Atherosclerotic Stenosis in China.
aStenosis in symptomatic patients was 50% and in asymptomatic patients
bStenosis in symptomatic patients was 50% and in asymptomatic patientsconducted a sensitivity analysis that included them.Methodologic quality. Table II summarizes the re-
ported methodologic quality of the included RCTs. The
reviewers had adequate agreement in judging study quality
(mean   0.83; range, 0.71-1.0). Six trials had adequate
allocation concealment, none of the trials blinded patients
or caregivers, and only two trials blinded data collectors and
outcome assessors. Five of the 10 trials were stopped pre-
maturely before reaching their planned sample size: one
each for futility,16 futility and harm,13 shortage of fund-
ing,14 slow enrollment,3 and harm.21 Both studies that
cited harm as a reason to stop early reported excess strokes
in the patients that received endovascular procedures.13,21
Meta-analysis. At 30 days and compared with CEA,
CAS was associated with a nonsignificant reduction in the
risk of death in five studies (RR, 0.61; 95% CI, 0.27-1.37;
I2  0%; Fig 2); a nonsignificant reduction in the risk of
nonfatal MI in 3 studies (RR, 0.43; 95% CI, 0.17-1.11;
I2  0%; Fig 3); and a nonsignificant increase in the risk of
any stroke in 5 studies (RR, 1.29; 95% CI, 0.73-2.26; I2
40%; Fig 4). When only major and disabling strokes were
included in the analysis, a similar nonsignificant increase in
the risk of stroke was noted in patients who received CAS in
4 studies (RR, 1.06; 95% CI, 0.32-3.52; I2  45%). When
only Q-wave MIs were included in analysis, data were very
limited and precludedmeaningful analysis (1 Q-waveMI in
the CAS group vs 4 in the CEA group). These results came
from only two trials,13,15 because the other trials did not
differentiate between Q and non-Q wave MI.
At 1 year and compared with CEA, CAS was associated
with a nonsignificant reduction in the risk of death in two
studies (RR, 0.56; 95% CI 0.29-1.08) and a nonsignificant
increase in the risks of stroke in two studies (RR, 1.35; 95%
CI, 0.31-5.82).
Equivalence analyses. Fig 5 describes 30-day equiva-
lence analysis. The available evidence is consistent with
Mean age of
subjects,
year Symptoms
Operative
risk
Follow-up,
months
Degree of
stenosis, %
67.2 Yes Average 1 70
68.3 Yes NR 12 60
68.0 Yes NR 48 70
67.0 Mixed Average 36 NR
68.2 No NR 48 80
72.6 Mixed High 36 50; 80a
69.7 Yes Average 6 60
67.9 Yes Average 1 70
63 Mixed NR 6 50; 70b
NR Yes NR 45 70
Artery Transluminal Angioplasty Study; EVA-3S, Endarterectomy Versus
rted; SAPPHIRE, Stenting and Angioplasty with Protection in Patients at
lasty Versus Carotid Endarterectomy; TESCAS-C, Treatment of Carotid
80%.
70%.ebral
ive
, %
0
ed)
tebral
t repo
ngiopequivalent effects of CEA and CAS on death and nonfatal
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on stroke would only be considered equivalent if an equiv-
alence zone of 3% is used. We consider this to be an
unacceptably wide zone of equivalence that could mask an
important benefit of CEA over CAS.
Subgroup and sensitivity analysis. Table III de-
scribes the results of our planned subgroup analyses. We
found no significant treatment–subgroup interaction for
subgroups on the basis of patient symptoms, the use of
protective devices, and stopping trials prematurely. We
found insufficient data to conduct the other planned sub-
group analyses. Within-trial subgroup analyses, that is, the
analyses presented in the original articles and not the ones
conducted across trials, failed to identify significant treat-
ment interactions based on the severity of stenosis,23 pa-
tient age and gender,14 the presence of symptoms,15 or
whether MI was associated with Q wave.15 These latter
analyses were reported in the individual trials, and we found
Fig 2. Meta-analysis of 30-day risk of death associated with ca-
rotid angioplasty and stenting (CAS) and endarterectomy (CEA).
Vertical line indicates no treatment effect, squares and horizontal
lines indicate relative risks (RR) and associated 95% confidence
intervals (CI) for each study, and diamonds indicate pooled relative
risks. Three additional trials18,21,22 reported this outcome but had
no events in either arm and did not contribute to the pooled
estimate.
Table II. Quality of trials
Author (year)
Allocation
concealment Patien
Naylor (1998)21,b Yes No
Alberts (2001)16 Probably not Probably
Brooks (2001)17,b Yes No
CAVATAS (2001)19,b No No
Brooks (2004)18,b Yes No
Yadav (2004)15 Yes Probably
Mas (2006)13,b No No
The SPACE group (2006)14,b Yes No
Ling (2006)20 Probably not Probably
Hoffman (2006)22 Yes Probably
CAVATAS, Carotid and Vertebral Artery Transluminal Angioplasty Study;
Angioplasty Versus Carotid Endarterectomy.
aNumber enrolled/planned sample size  100.
bAuthor was successfully contacted.insufficient data to conduct them between trials.The inclusion of CAVATAS19 and Leicester21 does not
change the conclusions of this review regarding death (RR,
0.85; 95% CI, 0.43-1.66; I2  0%) and stroke (RR, 1.25;
95% CI, 0.77-2.02; I2 42%). TheMI outcome, however,
becomes statistically significant, with a lower incidence of
MI with CAS (RR, 0.39; 95% CI, 0.16-0.96; I2 0%). The
clinical significance of this finding is unknown considering
that this was a mix of Q and non-Q wave MIs.
We compared three other statistical methods for conti-
nuity correction to allow the inclusion of studies with sparse
data. The pooled estimates for death, stroke, and MI were
not significantly affected by the choice of method. Simi-
larly, the inclusion of trials with zero total events14,17,18,21
did not significantly affect RRs of the three outcomes to the
extent that RRs continued to be imprecise and crossed the
line of no effect (RR, 1.0).
Lastly, we repeated analysis by using the fixed-effect
model to ascertain the magnitude of the effect of hetero-
Fig 3. Meta-analysis of 30-day risk of nonfatal myocardial infarc-
tion (MI) associated with carotid angioplasty and stenting (CAS)
and endarterectomy (CEA). Vertical line indicates no treatment
effect, squares and horizontal lines indicate relative risks (RR) and
associated 95% confidence intervals (CI) for each study, and dia-
monds indicate pooled relative risks. Four additional trials14,17,18,21
reported this outcome but had no events in either arm and did not
contribute to the pooled estimate.
Blinding
Caregivers Data collectors Outcome assessors
No No No
Probably not Probablynot Probablynot
No Yes No
No No Yes
No Yes No
Probably not Probablynot Probablynot
No No Yes
No No No
Probably not Probablynot Probablynot
Probably not Probablynot Probablynot
Not applicable; NR, not reported; SPACE, Stent-Protected Percutaneousts
not
not
not
not
N/A,geneity on results (both models are shown in Figs 2, 3, and
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heterogeneity (ie, I2  0%); however, the outcome of any
stroke became more precise and its CI became narrower
under the fixed-effect model.
DISCUSSION
Our findings. We conducted a systematic review and
meta-analyses of RCTs comparing CAS and CEA for ca-
rotid stenosis. We found 10 trials that provided low to
moderate quality evidence given that they poorly reported
or implemented bias protection measures. Although blind-
ing of patients and surgeons is often not feasible in surgical
trials, blinding of data collectors and outcome assessors,
and allocation concealment are possible. In addition, half of
the trials were stopped early and yielded imprecise results
on the outcome of stroke, which is the main outcome these
two procedures are primarily intended to prevent. Both
procedures appear equivalent on their effects on death and
nonfatal MI; the difference in risk of strokes between
procedures remains inconclusive, with a trend toward su-
periority favoring CEA. This trend is likely clinically impor-
tant considering that patients seek these procedures exclu-
Fig 4. Meta-analysis of 30-day risk of any stroke associated with
carotid artery angioplasty and stenting (CAS) and endarterectomy
(CEA). Vertical line indicates no treatment effect, squares and
horizontal lines indicate relative risks (RR) and associated 95%
confidence intervals (CI) for each study, and diamonds indicate
pooled relative risks. Two additional trials17,18 reported this out-
come but had no events in either arm and did not contribute to the
pooled estimate.
Table II. Continued.
% Lost to follow-up at 30 days Funding
0 Mixed
NR For profit
0 Mixed
0 Not for profit
0 Not for profit
NR Mixed
0 Not for profit
0 Mixed
NR Not for profit
NR NRsively to prevent stroke and because more of the CI of therisk difference lies in the region consistent with increased
risk of stroke. Limited data were available for subgroup
analyses, which appeared to have wide CI and were under-
powered.
Limitations and strengths of this review. Several
limitations weaken the inferences we can draw in this
review. The primary evidence is of low to moderate quality
due to themethodologic features of primary studies and the
imprecise results.24 Reporting bias may affect the results of
this review because one trial reported only composite out-
comes and did not contribute to the pooled estimates of
individual outcomes, and two trials were unpublished and
were only available as abstracts.16,22 In addition, five of
these 10 trials were halted before reaching their planned
sample size, citing reasons of futility, shortage of enroll-
ment, slow enrollment, or harm. Stopping RCTs prema-
turely for futility produces imprecise results that, as is the
case of the outcome of stroke in the present review, cannot
be made precise enough even after pooling, thus reducing
the scientific and societal value of this research.25-27
Applicability of our results may be limited because
Fig 5. Equivalence analysis for 30-day outcomes for carotid an-
gioplasty and stenting (CAS) and endarterectomy (CEA) using
pooled risk difference percentages, 95% confidence intervals (CI),
and theoretic equivalence margins.
Early termination Percentage of enrollmenta
For harm 7
For futility 31
No N/A
No N/A
No N/A
For slow enrollment NR
For futility and harm 60
For funding shortage 63
No N/A
No N/Asome trials selected participant clinicians and centers on the
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experience and learning curve. Although most trials de-
scribed these attributes, none of them had enough power
to adjust their analysis accordingly.
It is also important to recognize that equivalence anal-
ysis is based on the risk difference and is highly dependent
on the control event rates (CEA event rates) in different
practice settings. For example, in a setting that deals with
patients with multiple comorbidities and a known higher
risk for preoperative death andMIs, CEA and CASmay not
be equivalent in these two outcomes.
Our use of state-of-the-art systematic search, data col-
lection, and summary methods, author contact to limit
reporting bias, explicit quality assessment, and parsimoni-
ous analyses represent the strengths of this work.
Comparison with previous reviews. Compared with
reviews done 5 years ago, our RR estimates are similar
despite pooling data from 1933 additional randomized
patients.5 Our results differ, however, from the results of
recent reviews. Compared with Ederle et al,28 our analysis
of the individual outcomes of death, stroke, and nonfatal MI
Table III. Subgroup analysesa
Outcome RR (95% CI)b
Interaction
test (P)
Death at 30 days
No use of cerebral
protection device 1.42 (0.46-4.42) .46
Using cerebral protection
device 0.64 (0.28-1.48)
Trials stopped early 0.66 (0.27-1.61) .32
Trials not stopped early 1.35 (0.46-3.97)
Symptomatic patients 0.73 (0.28-1.93) .86
Asymptomatic patientsc 0.95 (0.06-16.36)
Stroke at 30 days
No use of cerebral
protection device 2.27 (0.16-31.46) .92
Using cerebral protection
device 1.51 (0.84-2.69)
Trials stopped early 2.24 (0.96-5.20) .12
Trials not stopped early 1.10 (0.76-1.60)
Symptomatic patients 2.08 (0.88-4.90) .60
Asymptomatic patientsc 0.95 (0.06-16.36)
Nonfatal MI at 30 days
No use of cerebral
protection device 0.19 (0.002-15.75) .72
Using cerebral protection
device 0.43 (0.17-1.11)
Trials stopped early 0.42 (0.15-1.16) .92
Trials not stopped early 0.48 (0.04-5.06)
Symptomatic patients 0.72 (0.14-3.72) .87
Asymptomatic patientsc 0.95 (0.06-16.36)
CI, Confidence interval; RR, relative risk.
aSubgroup analysis is conducted by calculating treatment effect from studies
with a particular trait (eg, studies in which protection devices were used) and
from studies without the trait (eg, studies in which protection devices were
not used).
bRandom-effect values 1.00 favor endarterectomy.
cOnly one study with zero events contributed to the pooled estimate of
asymptomatic patients.included one additional trial.20 Compared with Brahmandamet al29 andRingleb et al,30 our review included two additional
trials.20,22 Our random-effects meta-analyses yielded esti-
mates with less precision (wider CIs) than the fixed-effects
meta-analyses used in the latter two reviews. We planned
and executed a random-effects approach given the undeni-
able inconsistency in patients, interventions, and out-
comes across the eligible trials that makes neglect of
these between-study differences—the key assumption in
the fixed-effects approach—unsatisfactory. To our knowl-
edge, the present review is the first to explore equivalence
using absolute risk measures. These analyses determined
the extent to which the two procedures are equivalent in
reducing the risk of death and nonfatal MI; however,
limited precision made it impossible to draw similar infer-
ences about their effect on the risk of stroke.
Implications for further research. The investigators
of ongoing trials (Carotid Revascularization Endarterec-
tomy vs. Stent Trial, International Carotid Stenting Study,
Carotid Stenting vs Surgery of Severe Carotid Artery Dis-
ease and Stroke Prevention in Asymptomatic Patients-1,
Asymptomatic Carotid Surgery Trial-2, Transatlantic
Asymptomatic Carotid Intervention Trial, Agostoni et al,
and Link et al)31-37 should consider continuing patient
recruitment until they reach the planned sample size of the
trial. If concerns about patient safety arise, we encourage
investigators to use rigorous statistical methods for stop-
ping early andmake interim data assessments “early looks at
the data” infrequent and as delayed as possible in the course
of a trial. Otherwise, these trials may produce similarly
imprecise results and leave patients and clinicians with
significant ambiguity about the best treatment option for
carotid stenosis. Indeed, it is plausible that these two pro-
cedures are effective but may offer distinct advantages in
different patient groups; for example, patients with com-
plex carotid anatomy, patients with tenuous cardiovascular
health, and centers with differential expertise for each of
these procedures. Subgroup inferences will require, how-
ever, the conduct of large RCTs with inclusion criteria that
permit high-risk patients to enter the trials.
CONCLUSION
Evidence of moderate quality is inconclusive in estab-
lishing superiority, noninferiority, or equivalence of stent-
ing vs endarterectomy of the carotid arteries in patients
with carotid stenosis at risk of stroke. Both procedures seem
equivalent in terms of death and nonfatal MI, but the effect
on stroke prevention remains unclear.
This article is dedicated to thememory of Dr RobertW.
Hobson II in honor of all his contributions to our under-
standing of the management of carotid disease.
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